1. Home
  2. AGEN vs LICN Comparison

AGEN vs LICN Comparison

Compare AGEN & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.14

Market Cap

126.2M

Sector

Health Care

ML Signal

HOLD

Logo Lichen China Limited

LICN

Lichen China Limited

HOLD

Current Price

$2.95

Market Cap

47.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGEN
LICN
Founded
1994
2004
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.2M
47.5M
IPO Year
2000
2023

Fundamental Metrics

Financial Performance
Metric
AGEN
LICN
Price
$3.14
$2.95
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$14.50
N/A
AVG Volume (30 Days)
639.2K
63.9K
Earning Date
11-10-2025
12-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$106,829,000.00
$37,641,000.00
Revenue This Year
$67.15
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.38
$2.57
52 Week High
$7.34
$40.00

Technical Indicators

Market Signals
Indicator
AGEN
LICN
Relative Strength Index (RSI) 26.40 42.22
Support Level $3.01 $2.80
Resistance Level $4.00 $3.11
Average True Range (ATR) 0.25 0.23
MACD -0.05 -0.01
Stochastic Oscillator 11.26 14.89

Price Performance

Historical Comparison
AGEN
LICN

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.

Share on Social Networks: